This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
by Zacks Equity Research
RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III INAVO120 study.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Analyst Blog Highlights Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust
by Zacks Equity Research
Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust are part of the Zacks top Analyst Blog.
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
Top Research Reports for Visa, AstraZeneca & Shell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AstraZeneca PLC (AZN) and Shell plc (SHEL), as well as two micro-cap stocks Ocean Power Technologies, Inc. (OPTT) and Wheeler Real Estate Investment Trust, Inc. (WHLR).
MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug
by Zacks Equity Research
The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study
by Zacks Equity Research
Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.
After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order?
by Urmimala Biswas
President Donald Trump's new executive order aiming to cut U.S. drug prices could benefit Tempus AI.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales
by Zacks Equity Research
BAYRY's first-quarter earnings beat expectations. Revenues miss estimates, mainly due to lower sales of its products in the Crop Science division.
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.
How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%
by Zacks Equity Research
The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
by Kinjel Shah
NVO and JAZZ report first-quarter results. AZN's asthma study on Breztri meets key goals.
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall.
AZN or ARGX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AZN vs. ARGX: Which Stock Is the Better Value Option?
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth
by Zacks Equity Research
AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products, Prolia, Xgeva, Repatha, Blincyto and Evenity beat estimates.
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
by Zacks Equity Research
IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.
Here's Why Astrazeneca (AZN) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs
by Zacks Equity Research
AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
by Zacks Equity Research
Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results.
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS
by Zacks Equity Research
Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS are included in this Analyst Blog.
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
by Urmimala Biswas
TEM stock rises for three successive days. Should you expect more upside ahead, or is it time to dump Tempus AI?